Cargando…

Exosome: A New Player in Translational Nanomedicine

Summary: Exosomes are extracellular vesicles released by the vast majority of cell types both in vivo and ex vivo, upon the fusion of multivesicular bodies (MVBs) with the cellular plasma membrane. Two main functions have been attributed to exosomes: their capacity to transport proteins, lipids and...

Descripción completa

Detalles Bibliográficos
Autores principales: Aheget, Houssam, Tristán-Manzano, María, Mazini, Loubna, Cortijo-Gutierrez, Marina, Galindo-Moreno, Pablo, Herrera, Concha, Martin, Francisco, Marchal, Juan Antonio, Benabdellah, Karim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463834/
https://www.ncbi.nlm.nih.gov/pubmed/32722531
http://dx.doi.org/10.3390/jcm9082380
_version_ 1783577224547401728
author Aheget, Houssam
Tristán-Manzano, María
Mazini, Loubna
Cortijo-Gutierrez, Marina
Galindo-Moreno, Pablo
Herrera, Concha
Martin, Francisco
Marchal, Juan Antonio
Benabdellah, Karim
author_facet Aheget, Houssam
Tristán-Manzano, María
Mazini, Loubna
Cortijo-Gutierrez, Marina
Galindo-Moreno, Pablo
Herrera, Concha
Martin, Francisco
Marchal, Juan Antonio
Benabdellah, Karim
author_sort Aheget, Houssam
collection PubMed
description Summary: Exosomes are extracellular vesicles released by the vast majority of cell types both in vivo and ex vivo, upon the fusion of multivesicular bodies (MVBs) with the cellular plasma membrane. Two main functions have been attributed to exosomes: their capacity to transport proteins, lipids and nucleic acids between cells and organs, as well as their potential to act as natural intercellular communicators in normal biological processes and in pathologies. From a clinical perspective, the majority of applications use exosomes as biomarkers of disease. A new approach uses exosomes as biologically active carriers to provide a platform for the enhanced delivery of cargo in vivo. One of the major limitations in developing exosome-based therapies is the difficulty of producing sufficient amounts of safe and efficient exosomes. The identification of potential proteins involved in exosome biogenesis is expected to directly cause a deliberate increase in exosome production. In this review, we summarize the current state of knowledge regarding exosomes, with particular emphasis on their structural features, biosynthesis pathways, production techniques and potential clinical applications.
format Online
Article
Text
id pubmed-7463834
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74638342020-09-04 Exosome: A New Player in Translational Nanomedicine Aheget, Houssam Tristán-Manzano, María Mazini, Loubna Cortijo-Gutierrez, Marina Galindo-Moreno, Pablo Herrera, Concha Martin, Francisco Marchal, Juan Antonio Benabdellah, Karim J Clin Med Review Summary: Exosomes are extracellular vesicles released by the vast majority of cell types both in vivo and ex vivo, upon the fusion of multivesicular bodies (MVBs) with the cellular plasma membrane. Two main functions have been attributed to exosomes: their capacity to transport proteins, lipids and nucleic acids between cells and organs, as well as their potential to act as natural intercellular communicators in normal biological processes and in pathologies. From a clinical perspective, the majority of applications use exosomes as biomarkers of disease. A new approach uses exosomes as biologically active carriers to provide a platform for the enhanced delivery of cargo in vivo. One of the major limitations in developing exosome-based therapies is the difficulty of producing sufficient amounts of safe and efficient exosomes. The identification of potential proteins involved in exosome biogenesis is expected to directly cause a deliberate increase in exosome production. In this review, we summarize the current state of knowledge regarding exosomes, with particular emphasis on their structural features, biosynthesis pathways, production techniques and potential clinical applications. MDPI 2020-07-26 /pmc/articles/PMC7463834/ /pubmed/32722531 http://dx.doi.org/10.3390/jcm9082380 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Aheget, Houssam
Tristán-Manzano, María
Mazini, Loubna
Cortijo-Gutierrez, Marina
Galindo-Moreno, Pablo
Herrera, Concha
Martin, Francisco
Marchal, Juan Antonio
Benabdellah, Karim
Exosome: A New Player in Translational Nanomedicine
title Exosome: A New Player in Translational Nanomedicine
title_full Exosome: A New Player in Translational Nanomedicine
title_fullStr Exosome: A New Player in Translational Nanomedicine
title_full_unstemmed Exosome: A New Player in Translational Nanomedicine
title_short Exosome: A New Player in Translational Nanomedicine
title_sort exosome: a new player in translational nanomedicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463834/
https://www.ncbi.nlm.nih.gov/pubmed/32722531
http://dx.doi.org/10.3390/jcm9082380
work_keys_str_mv AT ahegethoussam exosomeanewplayerintranslationalnanomedicine
AT tristanmanzanomaria exosomeanewplayerintranslationalnanomedicine
AT maziniloubna exosomeanewplayerintranslationalnanomedicine
AT cortijogutierrezmarina exosomeanewplayerintranslationalnanomedicine
AT galindomorenopablo exosomeanewplayerintranslationalnanomedicine
AT herreraconcha exosomeanewplayerintranslationalnanomedicine
AT martinfrancisco exosomeanewplayerintranslationalnanomedicine
AT marchaljuanantonio exosomeanewplayerintranslationalnanomedicine
AT benabdellahkarim exosomeanewplayerintranslationalnanomedicine